BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) made an announcement, according to which the FDA has granted accelerated approval for vosoritide in children age 5 or older with achondroplasia and active growth plates.

The company plans to fully launch Voxogo in the US in December with net pricing of around $240,000 per patient per year, slightly below the company's initial launch pricing in the EU. Management spoke positively toward their pre-launch activities noting expectations for Voxogo to represent the company's largest launch and potentially highest grossing product to date.